PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
12808005-6	2003	The D1 receptor antagonist R-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SCH 23390) increased and the D1 receptor agonist 2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine (SKF 33939) decreased anandamide content.	1,2,3,4-tetrahydroisoquinoline-7-sulfonamide	216-219	dopamine receptor D1	Mus musculus	4-15	
1974856-3	1990	D1 receptor stimulation with SKF 38393 produced up to 90%, dose-related increases in neostriatal cGMP, whereas D1 antagonism with SCH 23390 decreased cGMP by 30% and blocked the increase induced by SKF 38393.	1,2,3,4-tetrahydroisoquinoline-7-sulfonamide	29-32	dopamine receptor D1	Mus musculus	0-11	
1974856-3	1990	D1 receptor stimulation with SKF 38393 produced up to 90%, dose-related increases in neostriatal cGMP, whereas D1 antagonism with SCH 23390 decreased cGMP by 30% and blocked the increase induced by SKF 38393.	1,2,3,4-tetrahydroisoquinoline-7-sulfonamide	198-201	dopamine receptor D1	Mus musculus	0-11	
18045908-6	2007	The D1-like agonist SKF 82958 (2,3,4,5,-tetrahydro-6-chloro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine hydrobromide) and the D2-like agonist quinelorane both functioned as positive reinforcers in wild-type mice but not in D1 receptor mutant mice, whereas food and intravenous injections of the opioid agonist remifentanil functioned as positive reinforcers in both genotypes.	1,2,3,4-tetrahydroisoquinoline-7-sulfonamide	20-23	dopamine receptor D1	Mus musculus	219-230	
10340822-1	1999	OBJECTIVE: We previously reported that a two week treatment with SKF 38393 (SKF, a dopamine D1 receptor agonist), plus bromocriptine (BC, a dopamine D2 receptor agonist) acted synergistically to normalize hyperphagia, body fat, hyperglycaemia and hyperlipidaemia in ob/ob mice.	1,2,3,4-tetrahydroisoquinoline-7-sulfonamide	65-68	dopamine receptor D1	Mus musculus	83-103	
10340822-1	1999	OBJECTIVE: We previously reported that a two week treatment with SKF 38393 (SKF, a dopamine D1 receptor agonist), plus bromocriptine (BC, a dopamine D2 receptor agonist) acted synergistically to normalize hyperphagia, body fat, hyperglycaemia and hyperlipidaemia in ob/ob mice.	1,2,3,4-tetrahydroisoquinoline-7-sulfonamide	76-79	dopamine receptor D1	Mus musculus	83-103